Research & Discovery

The latest research news in genetics and genomics.

The company entered a securities purchase agreement through which it has raised gross proceeds of $650,000 and paid down a portion of the company's debt.

The study aims to understand the willingness of individuals with a clinical diagnosis of familial hypercholesterolemia and their family members to undergo confirmatory genetic testing.

The company posted Q1 revenues of $7.5 million, up from $5.3 million in Q1 2017 and above the consensus Wall Street estimate of $7.1 million.

Freenome will leverage proteomics firm Biognosys' technology to add protein quantification to the development of Freenome's first commercially available screening test.

In a recent study, Mills and his colleagues determined the platform has suitable throughput, quantitative performance, and reproducibility for the clinic.